Breast Cancer Incidence Lowered by GLP-1 Agonists
BREAST cancer risks may be modified by weight-loss therapies, according to a recent retrospective cohort study published by McDonald et al.. Investigators analyzed electronic health records from 111,646 overweight or obese women aged 45 to 80 years who underwent breast imaging between January 1, 2022, and June 30, 2025. The primary objective was to discover whether an association exists between GLP-1 agonists and breast cancer incidence in screening-eligible women.
Among the total population, 15,264 women had prior or current exposure to GLP-1 agonists, while 96,382 did not. Breast cancer was diagnosed in 1.62% of the exposed group compared to 2.47% of the unexposed group, demonstrating a significant raw reduction. To account for potential confounding factors, researchers utilized propensity score matching based on age, race, ethnicity, maximum BMI, breast density, and type 2 diabetes history, yielding 30,528 well-aligned observations.
Clinical Protective Effects and Future Directions
The matched logistic regression analysis confirmed that exposure to GLP-1 agonists was associated with a 30.5% lower incidence of breast cancer. The protective association remained robust across clinical subgroups. In the matched dataset, the absolute risk reduction was 0.69%. Subgroup analyses revealed protective trends for both Black women and white women.
The findings offer an intriguing alternative for preventive care, as traditional chemoprevention options carry serious adverse profiles that often outweigh their benefits in average-risk patients. While the exact cellular pathways remain an active area of investigation, growing evidence suggests that these medications may inhibit tumor proliferation directly or reduce systemic inflammation independently of weight loss. Authors noted that observational data cannot establish direct causality or clarify dose-response relationships. Ultimately, the investigators emphasized that these hypothesis-generating results support the immediate need for prospective randomized trials to investigate these therapies for definitive breast cancer prevention.
Reference
McDonald ES et al. GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. JCO Oncol Pract. 2026;00(1-8). DOI: https://doi.org/10.1200/OP-26-00485
Featured Image: medical professional consulting patient on Adobe Stock.
- Author:
